바로가기
메인메뉴로 바로가기
콘텐츠 바로가기
하단메뉴로 바로가기
패밀리사이트 바로가기


진료과

  • 연세암병원-종양내과, 대장암센터, 비뇨기암센터

전문진료분야

  • <종양내과> 대장암, 비뇨기암, 항암약물치료, 신약치료

진료시간표

인터넷진료예약
의사시간표
진료시간
오전 암병원 암병원
오후 암병원

교육 및 임상 경력

  • 1998.05-2000.12  연세대학교  의과대학  내과학교실  강사
  • 2000.01-2003.12  국민보험공단  일산병원  혈액종양내과  전문의
  • 2004.01-2005.02  국립암센터  대장암센터  전문의
  • 2005.03-2007.02  연세대학교  의과대학  내과학교실  조교수
  • 2007.03-2012.02  연세대학교  의과대학  내과학교실  부교수
  • 2007.03-2008.08  세브란스병원  호스피스실  실장
  • 2013.03-2017.02  연세암병원  종양내과  과장
  • 2012.03-현        재  연세대학교  의과대학  내과학교실  교수
  • 2013.03-현        재  연세암병원  대장암센터  센터장
  • 2016.09-현        재  세브란스병원  임상연구관리실  임상시험센터  소장

학술관련경력

  • 대한내과학회
  • 대한암학회
  • 한국임상암학회
  • 대한내과학회 관리위원 (혈액종양분과장)
  • 대한암학회, 대한종양내과학회 이사
  • 한국임상암학회 총무이사 역임
  • 항암요법연구회 홍보위원장 역임
  • 미국암학회(ASCO) 정회원
  • 미국암연구학회(AACR) corresponding member
  • 유럽암학회 (ESMO) 정회원

주요 관심분야

  • 대장암의 항암약물치료. 신약 임상시험. 개인 맞춤치료

학력사항

  • 1990 연세대학교 의과대학 학사
  • 1994 연세대학교 의과대학 석사
  • 2003 연세대학교 의과대학 박사

논문

  • Xu RH, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS, Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2018 Mar 16. pii: S1470-2045(18)30140-2.
  • Cho YJ, Kim SH, Kim EK, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SY, Jung ST, Kim HS. Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma. BMC Cancer. 2018 Feb 7;18(1):158.
  • Xu J, Kim TW, Shen L, Sriuranpong V, Pan H, Xu R, Guo W, Han SW, Liu T, Park YS, Shi C, Bai Y, Bi F, Ahn JB, Qin S, Li Q, Wu C, Ma D, Lin D, Li J. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. J Clin Oncol. 2018 Feb 1;36(4):350-358
  • Byun JH, Ahn JB, Kim SY, Kang JH, Zang DY, Kang SY, Kang MJ, Shim BY, Baek SK, Kim BS, Lee KH, Lee SI, Cho SH, Sohn BS, Kim S, Hwang IG, Nam EM, Seo BG, Oh SC, Lee MA, Lee SC, Hong JH, Park YS. The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study. Korean J Intern Med. 2017 Nov 28.
  • Yoshino T1, Arnold D2, Taniguchi H3, Pentheroudakis G4, Yamazaki K5, Xu RH6, Kim TW7, Ismail F8, Tan IB9, Yeh KH10, Grothey A11, Zhang S12, Ahn JB13, Mastura MY14, Chong D9, Chen LT15, Kopetz S16, Eguchi-Nakajima T17, Ebi H18, Ohtsu A1, Cervantes A19, Muro K3, Tabernero J20, Minami H21, Ciardiello F22, Douillard JY23. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018 Jan 1;29(1):44-70
  • Kim CG, Ahn JB, Jung M, Beom SH, Heo SJ, Kim JH, Kim YJ, Kim NK, Min BS, Koom WS, Kim H, Roh YH, Ma BG, Shin SJ. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer. Ann Surg Oncol. 2017 Jan;24(1):227-235 (2nd author)
  • Kim CG, Ahn JB, Jung M, Beom SH, Kim C, Kim JH, Heo SJ, Park HS, Kim JH, Kim NK, Min BS, Kim H, Koom WS, Shin SJ. Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. Br J Cancer. 2016 Jun 28;115(1):25-33. (2nd author)
  • Kim SH, Park KH, Shin SJ, Lee KY, Kim TI, Kim NK, Rha SY, Roh JK, Ahn JB. p16 Hypermethylation and KRAS Mutation are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with mCRC. Cancer Res Treat. 2016 Jan;48(1):208-15 (Corresponding author)
  • Jung M, Shin SJ, Koom WS, Jung I, Keum KC, Hur H, Min BS, Baik SH, Kim NK, Kim H, Lim JS, Hong SP, Kim TI, Roh JK, Park YS, Ahn JB. A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):1015-22 (Corresponding author)
  • Lim SM, Jung M, Shin SJ, Baek SJ, Hur H, Min BS, Baik SH, Kim NK, Ahn JB. Clinical Implications from a Single-Center Study of Colorectal Adenocarcinoma in Transplant Recipients. Oncology. 2015:88(4):195-200. (Corresponding author)
  • Park CH, Rha SY, Ahn JB, Shin SJ, Kwon WS, Kim TS, An S, Kim NK, Yang WI, Chung HC. PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity. Int J Cancer. 2014 Oct 23 (3rd author)
  • Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, Park JO, Kim SY, Kim TY, Kim JH, Ahn JB, Lim SB, Yu CS, Kim JC, Yun SH, Kim JH, Park JH, Park HC, Jung KH, Kim TW. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014 Oct;15(11):1245-53
  • Lee HY, Ahn JB, Rha SY, Chung HC, Park KH, Kim TS, Kim NK, Shin SJ. High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients. World J Surg Oncol. 2014 Jul 24;12:232 (2nd author)
  • Yi JH, Kim H, Jung M, Shin SJ, Choi JS, Choi GH, Baik SH, Min BS, Kim NK, Ahn JB. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia. Oncology. 2013;85(5):283-9 (Corresponding author)
  • Kim SH, Shin SJ, Lee KY, Kim H, Kim TI, Kang DR, Hur H, Min BS, Kim NK, Chung HC, Roh JK, Ahn JB. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study. Ann Surg Oncol. 2013 Oct;20(11):3407-13 (Corresponding author)
  • Kim KY, Cha IH, Ahn JB, Kim NK, Rha SY, Chung HC, Roh JK, Shin SJ. Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study. J Surg Oncol. 2013 May;107(6):613-8 (3rd author)
  • Kim GM, Ahn JB, Rha SY, Kim HS, Kang B, Kim MW, Choi SY, Roh JK, Chung HC, Kim NK, Shin SJ. Changing treatment patterns in elderly patients with resectable colon cancer. Asia Pac J Clin Oncol. 2013 Sep;9(3):265-72. (2nd author)
  • Shin SJ, Ahn JB, Park KS, Lee YJ, Hong YS, Kim TW, Kim HR, Rha SY, Roh JK, Kim DH, Kim C, Chung HC. A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. Invest New Drugs. 2012 Apr;30(2):672-80 (2nd author)
  • Shin SJ, Ahn JB, Choi JS, Choi GH, Lee KY, Baik SH, Min BS, Hur H, Roh JK, Kim NK. Implications of clinical risk score to predict outcomes of liver-confined metastasis of colorectal cancer. Surg Oncol. 2012 Sep;21(3):e125-30. (2nd anthor)
  • Shin SJ, Hwang JW, Ahn JB, Rha SY, Roh JK, Chung HC. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent. Invest New Drugs. 2012 Apr 27. [Epub ahead of print] (3rd author)
  • Shin SJ, Jung M, Jeung HC, Kim HR, Rha SY, Roh JK, Chung HC, Ahn JB. A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. Invest New Drugs. 2012 Aug;30(4):1501-10 (Corresponding author)
  • Kim SH, Shin SJ, Kim SY, Lee SH, Park YS, Park SH, Lee KH, Kim TW, Hong YS, Ahn JB. Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial. Cancer Chemother Pharmacol. 2012 Jan;69(1):91-7. (Corresponding author)
  • Kim HR, Min BS, Kim JS, Shin SJ, Ahn JB, Rho JK, Kim NK, Rha SY. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis. Oncology. 2011;81(3-4):175-83
  • Kim HS, Hong MH, Kim K, Shin SJ, Ahn JB, Jeung HC, Chung HC, Koh Y, Lee SH, Bang YJ, Rha SY. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology. 2011;80(5-6):395-405
  • Shin SJ, Jeong JH, Park YS, Lee KH, Shim BY, Kim TW, Oh do Y, Lee MA, Kim YT, Kim YH, Zang DY, Roh JK, Ahn JB. Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer. Invest New Drugs. 2011 Oct;29(5):1073-80. (Corresponding author)
  • Ahn JB, Chung WB, Maeda O, Shin SJ, Kim HS, Chung HC, Kim NK, Issa JP. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer. 2011;117:1847-54 (First Author)
  • Hur H, Kim NK, Yun M, Min BS, Lee KY, Keum KC, Ahn JB, Kim H. (18)Fluoro-deoxy-glucose positron emission tomography in assessing tumor response to preoperative chemoradiation therapy for locally advanced rectal cancer. J Surg Oncol. 2010 Sep 30. [Epub ahead of print]
  • Kim JW, Kim YB, Kim NK, Min BS, Shin SJ, Ahn JB, Koom WS, Seong J, Keum KC. The role of adjuvant pelvic radiotherapy in rectal cancer with synchronous liver metastasis: a retrospective study. Radiat Oncol. 2010 Aug 31;5(1):75.
  • Joo EH, Rha SY, Ahn JB, Kang HY. Economic and patient-reported outcomes of outpatient home-based versus inpatient hospital-based chemotherapy for patients with colorectal cancer. Support Care Cancer. 2010 May 23. [Epub ahead of print]
  • Kim JS, Kim NK, Min BS, Hur H, Ahn JB, Keum KC. Adjuvant radiotherapy following total mesorectal excision for stage IIA rectal cancer: is it beneficial? Int J Colorectal Dis. 2010 Sep;25(9):1103-10..
  • Jung M, Ahn JB, Chang JH, Suh CO, Hong S, Roh JK, Shin SJ, Rha SY. Brain metastases from colorectal carcinoma: prognostic factors and outcome. J Neurooncol. 2010 May 14. [Epub ahead of print]
  • Shin SJ, Kim NK, Keum KC, Kim HG, Im JS, Choi HJ, Baik SH, Choen JH, Jeung HC, Rha SY, Roh JK, Chung HC, Ahn JB. Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. Radiother Oncol. 2010 Jun;95(3):303-7 (Corresponding Author)
  • Ahn JB, Rha SY, Shin SJ, Jeung HC, Kim TS, Zhang X, Park KH, Noh SH, Roh JK, Chung HC. Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. Cancer Lett. 2010 Feb 1;288(1):124-32. (First Author)
  • Shin SJ, Jeung HC, Ahn JB, Rha SY, Roh JK, Park KS, Kim DH, Kim C, Chung HC. A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Invest New Drugs. 2010 Oct;28(5):650-8.
  • Park S, Shin SJ, Ahn JB, Jeung HC, Rha SY, Lee SK, Chung HC. Benefits of recurrent colonic stent insertion in a patient with advanced gastric cancer with carcinomatosis causing colonic obstruction. Yonsei Med J. 2009 Apr 30;50(2):296-9.
  • Im CK, Rha SY, Jeung HC, Ahn JB, Shin SJ, Noh SH, Roh JK, Chung HC. A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer. Am J Clin Oncol. 2010 Feb;33(1):56-60.
  • Jeung HC, Rha SY, Shin SJ, Ahn JB, Noh SH, Roh JK, Chung HC. Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer. Jpn J Clin Oncol. 2010 Jan;40(1):29-35.
  • Kim YW, Kim NK, Min BS, Lee KY, Sohn SK, Cho CH, Kim H, Keum KC, Ahn JB. The prognostic impact of the number of lymph nodes retrieved after neoadjuvant chemoradiotherapy with mesorectal excision for rectal cancer. J Surg Oncol. 2009 Jul 1;100(1):1-7.
  • Kim JS, Hur H, Kim NK, Kim YW, Cho SY, Kim JY, Min BS, Ahn JB, Keum KC, Kim H, Sohn SK, Cho CH. Oncologic outcomes after radical surgery following preoperative chemoradiotherapy for locally advanced lower rectal cancer: abdominoperineal resection versus sphincter-preserving procedure. Ann Surg Oncol. 2009 May;16(5):1266-73.
  • Jeung HC, Rha SY, Park CH, Im CK, Shin SJ, Ahn JB, Noh SH, Roh JK, Chung HC. Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer. Int J Oncol. 2009 Mar;34(3):787-96.
  • Lee J, Jung KH, Park YS, Ahn JB, Shin SJ, Im SA, Oh DY, Shin DB, Kim TW, Lee N, Byun JH, Hong YS, Park JO, Park SH, Lim HY, Kang WK. Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemother Pharmacol. 2009 Sep;64(4):657-63.
  • Kwon WS, Rha SY, Jeung HC, Ahn JB, Jung JJ, Noh SH, Chung HC. G-T haplotype (2677G>T/A and 3435C>T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern. Cancer Lett. 2009 May 18;277(2):155-63.
  • Chang H, Rha SY, Jeung HC, Im CK, Ahn JB, Kwon WS, Yoo NC, Roh JK, Chung HC. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol. 2009 Feb;20(2):272-7. Epub 2008 Oct 3.
  • Jeung HC, Rha SY, Shin SJ, Ahn JB, Roh JK, Park CH, Noh SH, Chung HC. Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials. Cancer Chemother Pharmacol. 2009 Apr;63(5):919-27. Epub 2008 Aug 20.
  • Park JK, Kim YW, Hur H, Kim NK, Min BS, Sohn SK, Choi YD, Kim YT, Ahn JB, Roh JK, Keum KC, Seong JS. Prognostic factors affecting oncologic outcomes in patients with locally recurrent rectal cancer: impact of patterns of pelvic recurrence on curative resection. Langenbecks Arch Surg. 2009 Jan;394(1):71-7. Epub 2008 Jul 29.
  • Shin SJ, Jeung HC, Ahn JB, Rha SY, Yoo NC, Roh JK, Noh SH, Chung HC. Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. Cancer Lett. 2008 Nov 8;270(2):269-76.
  • Choi HJ, Kim NK, Keum KC, Cheon SH, Shin SJ, Baik SH, Choen JH, Rha SY, Roh JK, Jeung HC, Chung HC, Ahn JB. Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer. Radiother Oncol. 2008 Jun;87(3):361-6. (Corresponding Author)
  • Cho BC, Ahn JB, Seong J, Roh JK, Kim JH, Chung HC, Sohn JH, Kim NK. Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients. BMC Cancer. 2008 Jan 15;8(1):8 (Corresponding Author)
  • Min BS, Kim NK, Ahn JB, Roh JK, Kim KS, Choi JS, Cha SH, Kim H. Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases. Onkologie. 2007 Dec;30(12):637-43. Epub 2007 Nov 30.
  • Baik SH, Lee WJ, Rha KH, Kim NK, Sohn SK, Chi HS, Cho CH, Lee SK, Cheon JH, Ahn JB, Kim WH. Robotic total mesorectal excision for rectal cancer using four robotic arms. Surg Endosc. 2007 Nov 20; [Epub ahead of print]
  • Kang JI, Chung HC, Kim SJ, Choi HJ, Ahn JB, Jeung HC, Namkoong K. Standardization of the Korean version of Mini-Mental Adjustment to Cancer (K-Mini-MAC) scale: factor structure, reliability and validity. Psychooncology: 2007 Oct 23; [Epub ahead of print]
  • Jeung HC, Rha SY, Shin SJ, Ahn JB, Noh SH, Roh JK, Chung HC. A phase II study of S-1 monotherapy administered for 2 weeks of a 3 week cycle in advanced gastric cancer patients with poor performance status. Br J Cancer 97:458-63, 2007
  • Jeung HC, Rha SY, Kim HK, Lim HY, Kim S, Kim SY, Gong SJ, Park CH, Ahn JB, Noh SH, Chung HC. Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations. Oncologist 12:543-54, 2007
  • Shin SJ, Lee HW, Kim SH, Ahn JB, Choi HJ, Cho BC, Jeung HC, Rha SY, Chung HC, Pyo JY, Roh JK. Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy. Acta Oncol 46:547-9, 2007
  • Shin SJ, Jeung HC, Ahn JB, Choi HJ, Cho BC, Rha SY, Yoo NC, Roh JK, Chung HC. Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. Cancer Chemother Pharmacol 61(1):157-165, 2008
  • Shin SJ, Ahn JB, Choi HJ, Cho BC, Jeung HC, Rha SY, Chung HC, Roh JK. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. Cancer Chemother Pharmacol 61(1):75-81, 2008
  • Jeung HC, Rha SY, Cho BC, Yoo NC, Roh JK, Roh WJ, Chung HC, Ahn JB. A Phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan and oxaliplatin containing regimens. Br J Cancer 95:1637-41, 2006 (Corresponding Author)
  • Ahn JB. Chemotherapy in Rectal Cancer. Korean J Gastroenterol 47:277-84, 2006
  • Cho BC, Kim JH, Kim CB, Sohn JH, Choi HJ, Lee YC, Ahn JB. Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer. Oncol rep 15:621-7, 2006 (Corresponding Author)
  • Cho BC, Kim EH, Choi HJ, Kim JH, Roh JK, Chung HC, Ahn JB, Lee JD, Lee JT, Yoo NC, Sohn JH. A Pilot Study of Trans-Arterial Injection of Holmiun-Chitosan Complex for Treatment of Small Hepatocellular Carcinoma. YMJ 46:799-805, 2005
  • Kim TH, Kim DY, Cho KH, Kim YH, Jung KH, Ahn JB, Chang HJ, Kim JY, Choi HS, Lim SB, Sohn DK, Jeong SY. Comparative Analysis of the Effects of Belly Board and Bladder Distension in Postoperative Radiotherapy of Rectal Cancer Patients. Strahlenther Onkol 181:601?5, 2005
  • Kim YH, Kim DY, Kim TH, Jung KH, Chang HJ, Jeong SY, Sohn DK, Choi HS, Ahn JB, Kim DH, Lim SB, Lee JS, Park JG. Usefulness of MR Volumetric Evaluation in Predicting Response to Preoperative Concurrent Chemoradiotherapy in Patients with Resectable Rectal Cancer. Int J Radiat Oncol Biol Phys 62(3):761-768, 2005
  • Chang HJ, Jung KH, Kim DY, Jeong SY, Choi HS, Kim YH, Sohn DK, Yoo BC, Lim SB, Kim DH, Ahn JB, Kim IJ, Kim JM, Yoon WH, Park JG. BAX, A Predictive Marker for Therapeutic Response to Preoperative Chemoradiotherapy in Rectal Carcinoma Patients. Hum Pathol. 36(4):364-71, 2005
  • Sohn DK, Jeong SY, Choi HS, Lim SB, Huh JM, Kim DH, Kim DY, Kim YH, Chang HJ, Jung KH, Ahn JB, Kim HK, Park JG. Single Immunochemical Fecal Occult Blood Test for Detection of Colorectal Neoplasia. Cancer Research and Treatment 37(1):20-23, 2005
  • Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
    ONCOLOGY 96/2 :59-69,2019
  • Treatment Outcomes of Re-irradiation in Locoregionally Recurrent Rectal Cancer and Clinical Significance of Proper Patient Selection
    FRONTIERS IN ONCOLOGY 9/Issue J :Article number 529-,2019
  • Screening for Lung Cancer Using Low-dose Chest Computed Tomography in Korean Long-term Colorectal Cancer Survivors
    Journal of Cancer Prevention 24/1 :48-53,2019
  • The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer.
    GASTRIC CANCER 22/1 :113-122,2019
  • T2-weighted signal intensity-selected volumetry for prediction of pathological complete response after preoperative chemoradiotherapy in locally advanced rectal cancer
    EUROPEAN RADIOLOGY 28/12 :5,231-5,240,2018
  • CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer
    YONSEI MEDICAL JOURNAL 59/5 :588-594,2018
  • BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 19/10 :3,164-3,178,2018
  • Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection
    CLINICAL COLORECTAL CANCER 17/3 :513-518,2018
  • Mapping of lateral pelvic lymph node recurrences in rectal cancer: a radiation oncologist's perspective
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 144/6 :1119-1128,2018
  • Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.
    BMC CANCER 18/1 :158-165,2018
  • A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors
    INVESTIGATIONAL NEW DRUGS 35/6 :773-781,2017
  • Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery
    BMC CANCER 17/615 :615-625,2017
  • Reduced pelvic field sparing anastomosis for postoperative radiotherapy in selected patients with mid?upper rectal cancer
    JOURNAL OF RADIATION RESEARCH 58/4 :559-566,2017
  • Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer
    ONCOLOGY LETTERS 14/2 :2,385-2,392,2017
  • Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer
    ANNALS OF SURGICAL ONCOLOGY 24/1 :227-235,2017
  • Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia
    ANNALS OF SURGERY 265/5 :946-953,2017
  • ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition
    BIOCHEMICAL PHARMACOLOGY 123/ :73-84,2017
  • Biomarker-Based Scoring System for Prediction of Tumor Response After Preoperative Chemoradiotherapy in Rectal Cancer by Reverse Transcriptase Polymerase Chain Reaction Analysis
    DISEASES OF THE COLON & RECTUM 59/12 :1,174-1,182,2016
  • Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer
    ANNALS OF SURGICAL ONCOLOGY 23/ :928-935,2016
  • Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial
    CANCER RESEARCH AND TREATMENT 48/4 :1,210-1,221,2016
  • Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers
    BRITISH JOURNAL OF CANCER 115/1 :25-33,2016
  • High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 142/9 :2051-2059,2016
  • Upfront Systemic Chemotherapy and Short-Course Radiotherapy with Delayed Surgery for Locally Advanced Rectal Cancer with Distant Metastases: Outcomes, Compliance, and Favorable Prognostic Factors
    PLOS ONE 11/8 :e0161475-,2016
  • Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.
    BMC CANCER 16/434 :1-7,2016
  • Prognostic implications of PIK3CA amplification in curatively resected liposarcoma
    ONCOTARGET 7/17 :24549-24558,2016
  • The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous unresectable metastasis: Study protocol for a randomized controlled trial.
    TRIALS 19/17 :34-,2016
  • Cardiopulmonary fitness, adiponectin, chemerin associated fasting insulin level in colorectal cancer patients
    SUPPORTIVE CARE IN CANCER 24/7 :2927-2935,2016
  • 수술 후 항암화학요법을 받는 대장암 환자들의 운동 인식에 대한 현상학적 연구
    한국체육학회지 55/1 :687-700,2016
  • Circumferential resection margin positivity after preoperative chemoradiotherapy based on magnetic resonance imaging for locally advanced rectal cancer: implication of boost radiotherapy to the involved mesorectal fascia
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 46/4 :316-322,2016
  • A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis
    RADIOTHERAPY AND ONCOLOGY 118/2 :369-374,2016
  • p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
    CANCER RESEARCH AND TREATMENT 48/1 :208-215,2016
  • MRI risk stratification for tumor relapse in rectal cancer achieving pathological complete remission after neoadjuvant chemoradiation therapy and curative resection
    PLOS ONE 11/1 :e0146235-,2016
  • A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 93/5 :1015-1022,2015
  • Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine
    CANCER RESEARCH AND TREATMENT 74/4 :781-789,2015
  • Leiomyosarcoma: investigation of prognostic factors for risk-stratification model
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 20/6 :1226-1232,2015
  • Clinical Implications from a Single-Center Study of Colorectal Adenocarcinoma in Transplant Recipients
    ONCOLOGY 88/4 :195-200,2015
  • Novel Methods for Clinical Risk Stratification in Patients with Colorectal Liver Metastases
    CANCER RESEARCH AND TREATMENT 47/2 :242-250,2015
  • Incorporation of Radiotherapy in the Multidisciplinary Treatment of Isolated Retroperitoneal Lymph Node Recurrence from Colorectal Cancer
    ANNALS OF SURGICAL ONCOLOGY 22/5 :1520-1526,2015
  • Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer
    AMERICAN JOURNAL OF CANCER RESEARCH 5/1 :72-86,2015
  • PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity
    INTERNATIONAL JOURNAL OF CANCER 136/10 :2273-2283,2015
  • Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children
    CANCER RESEARCH AND TREATMENT 47/1 :9-17,2015
  • Exercise Barriers in Korean Colorectal Cancer Patients
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION 15/18 :7539-7545,2014
  • Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 74/4 :799-808,2014
  • High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients
    WORLD JOURNAL OF SURGICAL ONCOLOGY 12/- :232-238,2014
  • Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
    JOURNAL OF SURGICAL ONCOLOGY 110/2 :214-221,2014
  • Vascular Soft-Tissue Sarcomas: A Prognostic Model from a Retrospective Single-Center Study
    ONCOLOGY 86/5-6 :329-335,2014
  • Can a Biomarker-Based Scoring System Predict Pathologic Complete Response After Preoperative Chemoradiotherapy for Rectal Cancer?
    DISEASES OF THE COLON & RECTUM 57/5 :592-601,2014
  • Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme linked immunosorbent assays (ELISAs) for biomarkers
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 140/3 :399-409,2014
  • Differential Expression of CD133 Based on Microsatellite Instability Status in Human Colorectal Cancer
    MOLECULAR CARCINOGENESIS 53/S1 :E1-E10,2014
  • Prognostic Value of Mucinous Histology Depends on Microsatellite Instability Status in Patients with Stage III Colon Cancer Treated with Adjuvant FOLFOX Chemotherapy: A Retrospective Cohort Study
    ANNALS OF SURGICAL ONCOLOGY 20/11 :3407-3413,2013
  • Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 72/4 :853-860,2013
  • Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 72/ :825-835,2013
  • Assessment of efficiency and safety of the comprehensive Chemotherapy Assistance Program for ordering oncology medications
    INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS 82/6 :504-513,2013
  • Changing treatment patterns in elderly patients with resectable colon cancer
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 9/3 :265-272,2013
  • Combination of CYP Inhibitor with MEK/ERK Inhibitor Enhances the Inhibitory Effect on ERK in BRAF Mutant Colon Cancer Cells
    ANTICANCER RESEARCH 33/6 :2499-2508,2013
  • Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
    SUPPORTIVE CARE IN CANCER 21/6 :1751-1759,2013
  • Therapeutic Strategies for Well-differentiated Papillary Mesothelioma of the Peritoneum.
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 43/10 :996-1003,2013
  • Chemoradiotherapy in squamous cell carcinoma of the anal canal: a single institution experience
    Radiation oncology journal 31/1 :25-33,2013
  • Estimating the Adjuvant Chemotherapy Effect in Elderly Stage II and III Colon Cancer Patients in an Observational Study
    JOURNAL OF SURGICAL ONCOLOGY 107/6 :613-618,2013
  • Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent
    INVESTIGATIONAL NEW DRUGS 31/1 :1-13,2013
  • Quantitative Analysis of ERK Signaling Inhibition in Colon Cancer Cell Lines Using Phospho-Specific Flow Cytometry
    ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY 34/ :309-316,2012
  • Molecular Markers Predict Distant Metastases After Adjuvant Chemoradiation for Rectal Cancer
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 84/5 :e577-e584,2012
  • Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells
    BMC GENOMICS 13/348 :-,2012
  • Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience
    BMC CANCER 12/1 :471-471,2012
  • Implications of clinical risk score to predict outcomes of liver-confined metastasis of colorectal cancer
    SURGICAL ONCOLOGY-OXFORD 21/3 :e125-e130,2012
  • Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 69/1 :91-97,2012
  • VIPoma that arose from the rectum in a 65-year-old male patient
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE 27/10 :1385-1386,2012
  • A phase i pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy
    INVESTIGATIONAL NEW DRUGS 30/4 :1501-1510,2012
  • A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy
    INVESTIGATIONAL NEW DRUGS 30/ :672-680,2012
  • DNA Methylation Predicts Recurrence From Resected Stage III Proximal Colon Cancer
    CANCER 117/9 :1847-1854,2011
  • Efficacy of Oxaliplatin-Based Chemotherapy in Curatively Resected Colorectal Cancer with Liver Metastasis
    ONCOLOGY 81/3-4 :175-183,2011
  • Upfront systemic chemotherapy and preoperative short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastases
    RADIATION ONCOLOGY 6/0 :99-99,2011
  • Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer
    INVESTIGATIONAL NEW DRUGS 29/5 :1073-1080,2011
  • Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles
    ONCOLOGY 80/5-6 :395-405,2011
  • A Randomized Phase 2 Study of Docetaxel and S-1 Versus Docetaxel and Cisplatin in Advanced Gastric Cancer With an Evaluation of SPARC Expression for Personalized Therapy
    CANCER 117/10 :2050-2057,2011
  • Economic and patient-reported outcomes of outpatient home-based versus inpatient hospital-based chemotherapy for patients with colorectal cancer
    SUPPORTIVE CARE IN CANCER 19/7 :971-978,2011
  • Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis
    ONCOLOGY REPORTS 25/3 :717-727,2011
  • Brain metastases from colorectal carcinoma: prognostic factors and outcome
    JOURNAL OF NEURO-ONCOLOGY 101/ :49-55,2011
  • 18Fluoro-deoxy-glucose positron emission tomography in assessing tumor response to preoperative chemoradiation therapy for locally advanced rectal cancer
    JOURNAL OF SURGICAL ONCOLOGY 103/1 :17-24,2011
  • The role of adjuvant pelvic radiotherapy in rectal cancer with synchronous liver metastasis: a retrospective study
    RADIATION ONCOLOGY 5/ :75-75,2010
  • Clinicopathologic Features of Metachronous or Synchronous Gastric Cancer Patients with Three or More Primary Sites
    Cancer Research and Treatment 42/4 :217-224,2010
  • Adjuvant radiotherapy following total mesorectal excision for stage IIA rectal cancer: is it beneficial?
    International Journal Of Colorectal Disease 25/9 :1103-1110,2010
  • A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer
    Investigational New Drugs 28/5 :650-658,2010
  • Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer
    Radiotherapy And Oncology 95/3 :303-307,2010
  • A Phase II Study of a Combined Biweekly Irinotecan and Monthly Cisplatin Treatment for Metastatic or Recurrent Gastric Cancer
    American Journal of Clinical Oncology-Cancer Clinical Trials 33/1 :56-60,2010
  • Two Dosages of Oral Fluoropyrimidine S-1 of 35 and 40 mg/m(2) bid: Comparison of the Pharmacokinetic Profiles in Korean Patients with Advanced Gastric Cancer
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 40/1 :29-35,2010
  • Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients
    Cancer Letters 288/1 :124-132,2010
  • Benefits of Recurrent Colonic Stent Insertion in a Patient with Advanced Gastric Cancer with Carcinomatosis Causing Colonic Obstruction
    Yonsei Medical Journal 50/2 :296-299,2009
  • Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 64/4 :657-663,2009
  • clinical value of ezrin expression in primary osteosarcoma
    Cancer Research And Treatment 41/3 :138-144,2009
  • Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in korea
    Cancer Research And Treatment 41/2 :67-72,2009
  • 초저위 직장암의 괄약근간 절제술 및 대장항문 문합술
    대한외과학회지 76/1 :28-35,2009
  • Oncologic outcomes after radical surgery following preoperative chemoradiotherapy for locally advanced lower rectal cancer: Abdominoperineal rResection versus sphincter-preserving procedure
    Annals Of Surgical Oncology 16/5 :1266-1273,2009
  • The prognostic impact of the number of lymph nodes retrieved after neoadjuvant chemoradiotherapy with mesorectal excision for rectal cancer
    Journal Of Surgical Oncology 100/1 :1-7,2009
  • Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer
    International Journal Of Oncology 34/3 :787-796,2009
  • G-T haplotype (2677G > T/A and 3435C > T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern
    Cancer Letters 277/2 :155-163,2009
  • Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 63/5 :919-927,2009
  • Association of the ABCB1 gene polymorphisms 2677G > T/A and 3435C > T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients
    Annals Of Oncology 20/2 :272-277,2009
  • Mobilized CD34(+) cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer
    Cancer Letters 270/2 :269-276,2008
  • Standardization of the Korean version of Mini-Mental Adjustment to Cancer (K-Mini-MAC) scale: factor structure, reliability and validity
    Psycho-Oncology 17/ :592-597,2008
  • Hypofractionated high-dose intensity-modulated radiotherapy (60 Gy at 2.5 Gy per fraction) for recurrent renal cell carcinoma: A case report
    Journal Of Korean Medical Science 23/ :740-743,2008
  • S-1 Monotherapy as a Neoadjuvant Treatment for Locally Advanced Gastric Cancer
    The Korean Journal Of Internal Medicine 23/1 :37-41,2008
  • 절제 불가능한 결장직장암의 원격전이 환자에서 표적치료제를 포함한 선행항암화학요법 후 시행한 근치적인 절제술
    대한대장항문학회지 24/3 :184-191,2008
  • T2 대장암에서 E-cadherin과 β-catenin 복합체 발현의 임상적 의의
    대한대장항문학회지 24/2 :91-99,2008
  • Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases
    Annals Of Oncology 19/ :1146-1153,2008
  • Robotic total mesorectal excision for rectal cancer using four robotic arms
    Surgical Endoscopy 22/ :792-797,2008
  • Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: Long-term results in 31 patients
    Bmc Cancer 8/ :-,2008
  • The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer
    Cancer Chemotherapy And Pharmacology 61/ :75-81,2008
  • Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer
    Cancer Chemotherapy And Pharmacology 61/ :157-165,2008
  • Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer
    Radiotherapy And Oncology 87/ :361-366,2008
  • Cetuximab in Combination with 5-Fluorouracil, Leucovorin and Irinotecan as a Neoadjuvant Chemotherapy in Patients with Initially Unresectable Colorectal Liver Metastases
    ONKOLOGIE 30/12 :637-643,2007
  • A Locally Advanced Breast Cancer with Difficult Differential Diagnosis of Carcinosarcoma and Atypical Medullary Carcinoma, which had Poor Response to Adriamycin- and ...
    BREAST CANCER RESEARCH AND TREATMENT 39/3 :134-137,2007
  • Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy
    ACTA ONCOLOGICA 46/4 :547-549,2007
  • Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations
    ONCOLOGIST 12/5 :543-554,2007
  • A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status
    BRITISH JOURNAL OF CANCER 97/ :458-463,2007
  • A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens
    BRITISH JOURNAL OF CANCER 95/ :1637-1641,2006
  • Long-term Survival after Surgical Resection for Liver Metastasis from Gastric Cancer: Two Case Reports
    CANCER RESEARCH AND TREATMENT 38/3 :184-188,2006
  • 직장암의 항암화학요법
    대한소화기학회지 47/4 :277-284,2006
  • Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
    ONCOLOGY REPORTS 15/ :621-627,2006
  • A pilot study of trans-arterial injection of 166Holmium-Chitosan complex for treatment of small hepatocellular carcinoma
    YONSEI MEDICAL JOURNAL 46/6 :799-805,2005
  • Usefule of magnetic resonance volumetric evaluation in predicting response to preoperative concurrent chemoradiotherapy in patients withtients with resectable rectal cancer
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS / :-,2005
  • Single Immunochemical Fecal Occult Blood Test for Detection of Colorectal Neoplasia
    CANCER RESEARCH AND TREATMENT 37/1 :20-23,2005
  • Comparative analysis of the effects of belly board and bladder distension in postoperative radiotherapy of rectal cacer patients
    STRAHLENTHERAPIE UND ONKOLOGIE 181/ :601-605,2005
  • Bax, a predictive marker for therapeutic response to ptroperative chemoradiotherapy in patents with rectal carcinoma
    HUMAN PATHOLOGY / :-,2005
  • The pattern of gene copy number changes in bilateral breast cancer surveyed by cDNA microarray-based comparative genomic hybridization.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 13/1 :17-24,2004
  • Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 167/2 :215-224,2001

안중배

콘텐츠 처음으로 이동

네크워크 링크안내/사이트 정보